omaveloxolone
oral, once-daily Nrf2 activator approved to treat Friedreich's ataxia from modification of oleanoic acid Biogen/Reata Acquisition, July 28, 2023 Reata Pharma, TX / Biogen, MA
Molecules of the Month
12 minute read
Nov. 7, 2023
Omaveloxolone: A Billion-Dollar Natural Product-Derived Reversible Covalent Nrf2/KEAP1 Modulator